Understanding Your Treatment Plan — Cycles, Weeks and Duration

An immunotherapy cycle is one full round of treatment: the infusion visit itself, plus the rest period that follows before the next one. It is not a fixed number of weeks on its own — the length of that rest period, called the interval, depends on the specific regimen your oncologist has prescribed for your case.

Each cycle usually includes more than the drip itself. Before the infusion, your care team checks blood counts, organ function, and asks about any new symptoms since your last visit — this is how immune-related side effects get caught early, not only at scheduled scan dates. The infusion is typically an outpatient, day-care procedure lasting 30 minutes to a couple of hours, after which most patients go home the same day.

It's worth being direct here: most people newly diagnosed with cancer are not automatic candidates for immunotherapy at all. This page describes the schedule for patients whose oncologist and tumour board have already confirmed eligibility — through biomarker testing and a review of the specific cancer type and stage — not a schedule that applies universally to every cancer patient reading it.

Source: general dosing patterns described in NCCN and ASCO patient-education material. Your oncologist sets the exact interval, dose, and regimen for your specific case — this table explains the pattern, not your personal schedule.

There is no fixed total number of cycles that applies to every patient. Most tumour boards plan an initial block of cycles, then reassess with imaging before deciding whether to continue, adjust, or stop — so duration follows how the cancer and body respond, not a preset calendar.

In practice, this usually means your first response assessment — typically PET-CT or CT imaging, coordinated at partner imaging centres — happens after a defined early block of cycles, often somewhere around the two- to three-month mark, though the exact timing is set by your oncologist for your regimen. If the scan shows the cancer is responding and side effects are manageable, treatment usually continues for further cycles with the same review pattern repeating. If it isn't working, or side effects become significant, your oncologist may change the plan, switch approach, or stop — these are all normal parts of the process, not signs that something has gone wrong.

For patients who do respond well, immunotherapy is sometimes continued for an extended period — a pattern described in NCCN patient-education guidance as a defined maximum duration for select approved regimens, such as up to around two years — but this is decided case by case and is never guaranteed to apply to any individual patient. Some patients are instead prescribed a short, fixed course before surgery rather than an open-ended schedule; if that's your situation, neoadjuvant immunotherapy before surgery follows a different logic worth reading separately.

1. 1

   Confirm diagnosis, staging and biomarker eligibility

   Your exact cancer type, stage, and biomarker results decide whether immunotherapy is an option at all, and which regimen might apply.

2. 2

   Baseline organ-function and safety checks

   Blood counts, hormone levels, and overall organ function are checked before the first cycle, since immunotherapy can occasionally affect them.

3. 3

   First cycle and early monitoring

   The first few cycles are usually watched most closely for new symptoms, since immune-related reactions most often — though not always — start earlier in treatment.

4. 4

   Imaging reassessment at a defined interval

   A scan — typically PET-CT or CT, coordinated at partner imaging centres — checks whether the cancer is responding, usually after an initial defined block of cycles.

5. 5

   The decision point: continue, adjust, or stop

   Based on the scan and how you've tolerated treatment, the tumour board decides whether to continue on the same schedule, change the regimen, pause for side effects, or stop.

• Immune-related side effects — a cycle may be delayed, or steroids started, if bloodwork or symptoms suggest inflammation in the gut, lungs, liver, or hormone glands.
• Infections or other illness — an active infection or a significant unrelated illness can push a cycle back until you're well enough for the next infusion.
• How the cancer is responding — a strong response can sometimes mean spacing cycles out in a maintenance phase; little or no response can mean stopping and changing approach.
• Logistics and cost — travel distance, work commitments, and the cost of each cycle are real, practical factors worth raising with your care team, not something to manage silently.

None of these changes are unusual. A schedule that gets adjusted partway through is a sign the plan is being actively managed — not that something has gone wrong.

You can raise pausing, stopping, or not starting immunotherapy with your oncologist at any point — it is your decision to make, not only theirs. For some patients, especially when side effects are significant or the cancer isn't responding, focusing on best supportive care instead is a legitimate, respected choice.

This isn't a decision your care team should ever make in secret or pressure you toward. If treatment feels like it's taking more from you — physically, financially, or emotionally — than it's realistically likely to give back, it's entirely reasonable to ask what stopping, or not starting, would actually look like. Comparing immunotherapy with best supportive care is a useful next read if this is a question you're sitting with.

• What Happens If You Do Nothing? Comparing Treatment With Best Supportive Care — the full picture if you're weighing whether to start, or continue, treatment at all.
• Immunotherapy Before Surgery: What Neoadjuvant Treatment Does — a shorter, different cycle pattern used before an operation, not the open-ended schedule this page describes.
• What Is Immunotherapy? How It Differs From Chemotherapy — the basics, if a schedule sheet is the first thing you've seen before understanding what the treatment itself does.
• Immunotherapy at CION Cancer Clinics — how CION supports patients through biomarker testing, day-care administration, and ongoing monitoring.

This page is for general information and does not replace a consultation. Immunotherapy is administered as day care at CION centres; response-assessment imaging is coordinated at partner imaging centres. Only your oncologist, reviewing your complete treatment plan, can tell you what your own schedule will look like.

Thousands of families have stared at a schedule sheet like yours

Our team walks through your specific cycles, interval, and expected duration with you — unhurried, and without pressure to proceed.